LTRN Lantern Pharma Secures USPTO Notice of Allowance for LP—284 Treatment Patent in Aggressive B—Cell Lymphomas
LTRN Lantern Pharma Secures USPTO Notice of Allowance for LP—284 Treatment Patent in Aggressive B—Cell Lymphomas
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results.
LTRN Lantern Pharma Secures USPTO Notice of Allowance for LP—284 Treatment Patent in Aggressive B—Cell Lymphomas